Regulatory Viridian wins FDA approval for Lumvoa for thyroid eye disease PharmaTimesCompany secures first commercial product with data for active and chronic TEDOphthalmologyRead full story pharminent June 29, 2026 (Last updated: June 30, 2026) PharmaTimes Company secures first commercial product with data for active and chronic TED Ophthalmology Read full story Post navigation Previous: Ipsen charts $1.75bn course for Kartos acquisitionNext: Biogen trims Apellis pipeline and R&D team after $5.6bn takeover Related Stories Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug pharminent August 31, 2026 Regulatory FDA green lights Priovant drug for rare skin disease pharminent August 28, 2026 Regulatory Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 pharminent August 26, 2026